These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18368021)

  • 1. The impact of corporate practices on health: implications for health policy.
    Freudenberg N; Galea S
    J Public Health Policy; 2008 Apr; 29(1):86-104; discussion 105. PubMed ID: 18368021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health advocacy to change corporate practices: implications for health education practice and research.
    Freudenberg N
    Health Educ Behav; 2005 Jun; 32(3):298-319; discussion 355-62. PubMed ID: 15851541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health campaigns to change industry practices that damage health: an analysis of 12 case studies.
    Freudenberg N; Bradley SP; Serrano M
    Health Educ Behav; 2009 Apr; 36(2):230-49. PubMed ID: 18077655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More than a message: framing public health advocacy to change corporate practices.
    Dorfman L; Wallack L; Woodruff K
    Health Educ Behav; 2005 Jun; 32(3):320-36; discussion 355-62. PubMed ID: 15851542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vioxx should be allowed back on the market advises expert panel.
    Sibbald B
    CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
    [No Abstract]   [Full Text] [Related]  

  • 6. Learning from international policies on trans fatty acids to reduce cardiovascular disease in low- and middle-income countries, using Mexico as a case study.
    Pérez-Ferrer C; Lock K; Rivera JA
    Health Policy Plan; 2010 Jan; 25(1):39-49. PubMed ID: 19741052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The manufacture of lifestyle: the role of corporations in unhealthy living.
    Freudenberg N
    J Public Health Policy; 2012 May; 33(2):244-56. PubMed ID: 22258282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keeping the focus on public health: the struggles of a tobacco prevention task force.
    Shillis JA; Hall BA; Sneden GG; Gottlieb NH
    Health Educ Behav; 2003 Dec; 30(6):771-88. PubMed ID: 14655869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empowerment to reduce health disparities.
    Wallerstein N
    Scand J Public Health Suppl; 2002; 59():72-7. PubMed ID: 12227969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ottawa 25 years on: a more radical agenda for health equity is still required.
    Baum FE; Sanders DM
    Health Promot Int; 2011 Dec; 26 Suppl 2():ii253-7. PubMed ID: 22080080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

  • 12. Banning smoking in cars carrying children: an analytical history of a public health advocacy campaign.
    Freeman B; Chapman S; Storey P
    Aust N Z J Public Health; 2008 Feb; 32(1):60-5. PubMed ID: 18290915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 14. The Demise of Artificial Trans Fat: A History of a Public Health Achievement.
    Amico A; Wootan MG; Jacobson MF; Leung C; Willett AW
    Milbank Q; 2021 Sep; 99(3):746-770. PubMed ID: 34342900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merck's actions surrounding Vioxx.
    Heinley M
    PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
    [No Abstract]   [Full Text] [Related]  

  • 16. 'Maximising shareholder value': a detailed insight into the corporate political activity of the Australian food industry.
    Mialon M; Swinburn B; Allender S; Sacks G
    Aust N Z J Public Health; 2017 Apr; 41(2):165-171. PubMed ID: 28110500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening a state's health advocacy infrastructure.
    Holton-Hodson R; Brousseau R
    Health Aff (Millwood); 2006; 25(3):856-9. PubMed ID: 16684752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

  • 19. Life after Vioxx.
    Underwood A
    Newsweek; 2005 Jan; 145(5):40-1. PubMed ID: 17896720
    [No Abstract]   [Full Text] [Related]  

  • 20. Merck's Careful Study of Vioxx.
    Mayer TV
    Am J Cardiol; 2008 Apr; 101(7):1068-9; author reply 1069. PubMed ID: 18359336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.